|  |  |  |  |
| --- | --- | --- | --- |
| **HLT-PT NAME** | **“Confirmed OI“****N=106** | **Concomitant medications** | **Concomitant medications per drug category** |
| **Herpes viral infections** | **72 (68%)** | 22 bio+mtx16 bio8 mtx5 bio+mtx+ste3 ste2 bio +sDMARDS\*2 bio +sDMARDS\*+mtx2 bio+ ste2 sDMARDs+mtx1 sDMARDs+mtx+ste1 sDMARDs+ste1 bio +sDMARDS\*+mtx+ste1 bio +sDMARDS\*+ste6 other | 51 bio41 mtx14 ste10 sDMARDs6 other |
| **Tuberculous infections** | **11 (10.4%)** | 5 bio+mtx2 bio+sDMARDs+mtx1 mtx+ste1 bio1 bio+mtx+ste1 bio+sDMARDs+mtx+ste | 10 bio10 mtx3 ste3 sDMARDs |
| **Candida infections** | **9 (8.5%)** | 3 ste3 bio+mtx1 bio+ste1 sDMARDs+ste1 other | 5 ste4 bio3 mtx1 other |
| **Papilloma viral infections** | **4 (3.8%)** | 3 mtx+ste1 bio | 3 mtx3 ste1 bio |
| **Pneumocystis infections** | **4 (3.8%)** | 2 sDMARDs+mtx+ste1 mtx1 mtx+ste | 4 mtx3 ste2 sDMARDs |
| **Cytomegaloviral infections** | **3 (2.8%)** | 1 mtx1 ste1 bio+ste | 2 ste1 bio1 mtx |
| **Aspergillus infections** | **1 (0.9%)** | 1 ste | 1 ste |
| **Leprous infections** | **1 (0.9%)** | 1 bio | 1 bio |
| **Infections NEC** | **1 (0.9%)** | 1 ste | 1 ste |

Additional table 2. Concomitant medications administered at the time of “confirmed OI”. Bio: biologic, mtx: methotrexate; ste: systemic steroids; sDMARDs: synthetic disease modifying antirheumatic drugs; \*sDMARDs are intendend other than MTX.